Combination therapy for gram-negative bacteria: What is the evidence?

Expert Review of Anti-Infective Therapy

Volumn 11, Issue 12, 2013, Pages 1355-1362

  Kmeid, Joumana G ^a   Youssef, Mona M ^a   Kanafani, Zeina A ^a   Kanj, Souha S ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

Anti microbial resistance; Carbapenems; Combination therapy; Gram negative; Synergy

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CARBAPENEM; CEFTAZIDIME; CIPROFLOXACIN; CLARITHROMYCIN; COLISTIN; COTRIMOXAZOLE; DOXYCYCLINE; ERTAPENEM; FOSFOMYCIN; GENTAMICIN; IMIPENEM; ISEPAMICIN; MEROPENEM; MINOCYCLINE; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN B; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SULBACTAM; SULTAMICILLIN; TETRACYCLINE DERIVATIVE; TICARCILLIN; TIGECYCLINE; TIMENTIN; TOBRAMYCIN; UNINDEXED DRUG;

ACINETOBACTER; ACINETOBACTER INFECTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL COLONIZATION; BACTERICIDAL ACTIVITY; BLOODSTREAM INFECTION; COMBINATION CHEMOTHERAPY; DRUG CHOICE; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTION; EVIDENCE BASED MEDICINE; GRAM NEGATIVE INFECTION; GRAM NEGATIVE SEPSIS; HUMAN; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE INFECTION; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MULTIDRUG RESISTANCE; NEPHROTOXICITY; NONHUMAN; OFF LABEL DRUG USE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STENOTROPHOMONAS MALTOPHILIA; SURVIVAL RATE; TREATMENT DURATION; VENTILATOR ASSOCIATED PNEUMONIA;

ANTI-BACTERIAL AGENTS; CARBAPENEMS; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FLUOROQUINOLONES; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MINOCYCLINE; POLYMYXINS; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 84888075146     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.2013.846215     Document Type: Review

References (61)

1. Kumar A, Safdar N, Kethireddy S, Chateau D. A survival benefit of combination antibiotic therapy for serious infections associated with sepsis and septic shock is contingent only on the risk of death: a meta-analytic/meta- regression study. Crit. Care Med. 38(8), 1651-1664 (2010).
2. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am. J. Respir. Crit. Care Med. 171(4), 388-416 (2005).
3. Peterson LR. Bad bugs, no drugs: no ESCAPE revisited. Clin. Infect. Dis. 49(6), 992-993 (2009).
4. Rice LB. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J. Infect. Dis. 197(8), 1079-1081 (2008).
5. Hilf M, Yu VL, Sharp J, Zuravleff JJ, Korvick JA, Muder RR. Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients. Am. J. Med. 87(5), 540-546 (1989).
6. Safdar N, Handelsman J, Maki DG. Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis. Lancet Infect. Dis. 4(8), 519-527 (2004).
7. Park SY, Park HJ, Moon SM et al. Impact of adequate empirical combination therapy on mortality from bacteremic Pseudomonas aeruginosa pneumonia. BMC Infect. Dis. 12,308. (2012).
8. Chamot E, Boffi El Amari E, Rohner P, Van Delden C. Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia. Antimicrob. Agents Chemother. 47(9), 2756-2764 (2003).
9. Paul M, Benuri-Silbiger I, Soares-Weiser K, Leibovici L. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. BMJ 328(7441), 668 (2004).
10. Bowers DR, Liew YX, Lye DC, Kwa AL, Hsu LY, Tam VH. Outcomes of appropriate empiric combination versus monotherapy for Pseudomonas aeruginosa bacteremia. Antimicrob. Agents Chemother. 57(3), 1270-1274 (2013).
11. Kanj SS, Kanafani ZA. Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa. Mayo Clin. Proc. 86(3), 250-259 (2011).
12. Zuravleff JJ, Yu VL, Yee RB. Ticarcillintobramycin-rifampin: in vitro synergy of the triplet combination against Pseudomonas aeruginosa. J. Lab. Clin. Med. 101(6), 896-902 (1983).
13. Dundar D, Otkun M. In-vitro efficacy of synergistic antibiotic combinations in multidrug resistant Pseudomonas aeruginosa strains. Yonsei Med. J. 51(1), 111-116 (2010).
14. Dubois V, Arpin C, Melon M et al. Nosocomial outbreak due to a multiresistant strain of Pseudomonas aeruginosa P12: efficacy of cefepime-amikacin therapy and analysis of beta-lactam resistance. J. Clin. Microbiol. 39(6), 2072-2078 (2001).
15. Fish DN, Choi MK, Jung R. Synergic activity of cephalosporins plus fluoroquinolones against Pseudomonas aeruginosa with resistance to one or both drugs. J. Antimicrob. Chemother. 50(6), 1045-1049 (2002).
16. Urena MT, Barasoain I, Espinosa M, Garcia E, Portoles A. Evaluation of different antibiotic actions combined with rifampicin. In vitro synergism against Pseudomonas and Proteus. Chemotherapy 21(2), 82-89 (1975).
17. Timurkaynak F, Can F, Azap OK, Demirbilek M, Arslan H, Karaman SO. In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units. Int. J. Antimicrob. Agents 27(3), 224-228 (2006).
18. Gunderson BW, Ibrahim KH, Hovde LB, Fromm TL, Reed MD, Rotschafer JC. Synergistic activity of colistin and ceftazidime against multiantibiotic- resistant Pseudomonas aeruginosa in an in vitro pharmacodynamic model. Antimicrob. Agents Chemother. 47(3), 905-909 (2003).
19. Lim TP, Lee W, Tan TY et al. Effective antibiotics in combination against extreme drug-resistant Pseudomonas aeruginosa with decreased susceptibility to polymyxin B. PLoS ONE 6(12), e28177 (2011).
20. Korvick JA, Peacock JE Jr, Muder RR, Wheeler RR, Yu VL. Addition of rifampin to combination antibiotic therapy for Pseudomonas aeruginosa bacteremia: prospective trial using the Zelen protocol. Antimicrob. Agents Chemother. 36(3), 620-625 (1992).
21. Saiman L, Chen Y, Gabriel PS, Knirsch C. Synergistic activities of macrolide antibiotics against Pseudomonas aeruginosa, Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans isolated from patients with cystic fibrosis. Antimicrob. Agents Chemother. 46(4), 1105-1107 (2002).
22. Falagas ME, Kastoris AC, Karageorgopoulos DE, Rafailidis PI. Fosfomycin for the treatment of infections caused by multidrug-resistant nonfermenting Gram-negative bacilli: a systematic review of microbiological, animal and clinical studies. Int. J. Antimicrob. Agents 34(2), 111-120 (2009).
23. Yigit H, Queenan AM, Anderson GJ et al. Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob. Agents Chemother. 45(4), 1151-1161 (2001).
24. Nordmann P, Naas T, Poirel L. Global spread of Carbapenemase-producing Enterobacteriaceae. Emerg. Infect. Dis. 17(10), 1791-1798 (2011).
25. Pournaras S, Vrioni G, Neou E et al. Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay. Int. J. Antimicrob. Agents 37(3), 244-247 (2011).
26. Souli M, Rekatsina PD, Chryssouli Z, Galani I, Giamarellou H, Kanellakopoulou K. Does the activity of the combination of imipenem and colistin in vitro exceed the problem of resistance in metallo-beta-lactamase-producing Klebsiella pneumoniae isolates? Antimicrob. Agents Chemother. 53(5), 2133-2135 (2009).
27. Bulik CC, Nicolau DP. Double-carbapenem therapy for carbapenemase- producing Klebsiella pneumoniae. Antimicrob. Agents Chemother. 55(6), 3002-3004 (2011).
28. Ceccarelli G, Falcone M, Giordano A et al. Successful ertapenem-doripenem combination treatment of bacteremic ventilator-associated pneumonia due to colistin-resistant KPC-producing Klebsiella pneumoniae. Antimicrob. Agents Chemother. 57(6), 2900-2901 (2013).
29. Giamarellou H, Galani L, Baziaka F, Karaiskos I. Effectiveness of a double-carbapenem regimen for infections in humans due to carbapenemase- producing pandrug-resistant Klebsiella pneumoniae. Antimicrob. Agents Chemother. 57(5), 2388-2390 (2013).
30. Souli M, Galani I, Boukovalas S et al. In vitro interactions of antimicrobial combinations with fosfomycin against KPC-2-producing Klebsiella pneumoniae and protection of resistance development. Antimicrob. Agents Chemother. 55(5), 2395-2397 (2011).
31. Qureshi ZA, Paterson DL, Potoski BA et al. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob. Agents Chemother. 56(4), 2108-2113 (2012).
32. Tzouvelekis LS, Markogiannakis A, Psichogiou M, Tassios PT, Daikos GL. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin. Microbiol. Rev. 25(4), 682-707 (2012).
33. Tumbarello M, Viale P, Viscoli C et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin. Infect. Dis. 55(7), 943-950 (2012).
34. Daikos GL, Petrikkos P, Psichogiou M et al. Prospective observational study of the impact of VIM-1 metallo-beta-lactamase on the outcome of patients with Klebsiella pneumoniae bloodstream infections. Antimicrob. Agents Chemother. 53(5), 1868-1873 (2009).
35. Zarkotou O, Pournaras S, Tselioti P et al. Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment. Clin. Microbiol. Infect. 17(12), 1798-1803 (2011).
36. Lim SK, Lee SO, Choi SH et al. The outcomes of using colistin for treating multidrug resistant Acinetobacter species bloodstream infections. J. Korean Med. Sci. 26(3), 325-331 (2011).
37. Song JY, Kee SY, Hwang IS et al. In vitro activities of carbapenem/sulbactam combination, colistin, colistin/rifampicin combination and tigecycline against carbapenem-resistant Acinetobacter baumannii. J. Antimicrob. Chemother. 60(2), 317-322 (2007).
38. Lee NY, Wang CL, Chuang YC et al. Combination carbapenem-sulbactam therapy for critically ill patients with multidrug-resistant Acinetobacter baumannii bacteremia: four case reports and an in vitro combination synergy study. Pharmacotherapy 27(11), 1506-1511 (2007).
39. Kuo LC, Lai CC, Liao CH et al. Multidrug-resistant Acinetobacter baumannii bacteraemia: clinical features, antimicrobial therapy and outcome. Clin. Microbiol. Infect. 13(2), 196-198 (2007).
40. Montero A, Ariza J, Corbella X et al. Antibiotic combinations for serious infections caused by carbapenem-resistant Acinetobacter baumannii in a mouse pneumonia model. J. Antimicrob. Chemother. 54(6), 1085-1091 (2004).
41. Bernabeu-Wittel M, Pichardo C, Garcia-Curiel A et al. Pharmacokinetic/pharmacodynamic assessment of the in-vivo efficacy of imipenem alone or in combination with amikacin for the treatment of experimental multiresistant Acinetobacter baumannii pneumonia. Clin. Microbiol. Infect. 11(4), 319-325 (2005).
42. Saballs M, Pujol M, Tubau F et al. Rifampicin/imipenem combination in the treatment of carbapenem-resistant Acinetobacter baumannii infections. J. Antimicrob. Chemother. 58(3), 697-700 (2006).
43. Tripodi MF, Durante-Mangoni E, Fortunato R, Utili R, Zarrilli R. Comparative activities of colistin, rifampicin, imipenem and sulbactam/ampicillin alone or in combination against epidemic multidrug-resistant Acinetobacter baumannii isolates producing OXA-58 carbapenemases. Int. J. Antimicrob. Agents 30(6), 537-540 (2007).
44. Sader HS, Rhomberg PR, Jones RN. In vitro activity of beta-lactam antimicrobial agents in combination with aztreonam tested against metallo-beta-lactamaseproducing Pseudomonas aeruginosa and Acinetobacter baumannii. J. Chemother. 17(6), 622-627 (2005).
45. Scheetz MH, Qi C, Warren JR et al. In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or - resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 51(5), 1621-1626 (2007).
46. Guner R, Hasanoglu I, Keske S, Kalem AK, Tasyaran MA. Outcomes in patients infected with carbapenem-resistant Acinetobacter baumannii and treated with tigecycline alone or in combination therapy. Infection 39(6), 515-518 (2011).
47. Entenza JM, Moreillon P. Tigecycline in combination with other antimicrobials: a review of in vitro, animal and case report studies. Int. J. Antimicrob. Agents 34(1),8. e1-9 (2009).
48. Dizbay M, Tozlu DK, Cirak MY, Isik Y, Ozdemir K, Arman D. In vitro synergistic activity of tigecycline and colistin against XDR-Acinetobacter baumannii. J. Antibiot. 63(2), 51-53 (2010).
49. Sheng WH, Wang JT, Li SY et al. Comparative in vitro antimicrobial susceptibilities and synergistic activities of antimicrobial combinations against carbapenem-resistant Acinetobacter species: Acinetobacter baumannii versus Acinetobacter genospecies 3 and 13TU. Diagn. Microbiol. Infect. Dis. 70(3), 380-386 (2011).
50. Cai Y, Chai D, Wang R, Liang B, Bai N. Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies. J. Antimicrob. Chemother. 67(7), 1607-1615 (2012).
51. Liang W, Liu XF, Huang J, Zhu DM, Li J, Zhang J. Activities of colistin- and minocycline-based combinations against extensive drug resistant Acinetobacter baumannii isolates from intensive care unit patients. BMC Infect. Dis. 11, 109 (2011).
52. Giamarellos-Bourboulis EJ, Karnesis L, Giamarellou H. Synergy of colistin with rifampin and trimethoprim/sulfamethoxazole on multidrug-resistant Stenotrophomonas maltophilia. Diagn. Microbiol. Infect. Dis. 44(3), 259-263 (2002).
53. Gulmez D, Cakar A, Sener B, Karakaya J, Hascelik G. Comparison of different antimicrobial susceptibility testing methods for Stenotrophomonas maltophilia and results of synergy testing. J. Infect. Chemother. 16(5), 322-328 (2010).
54. Looney WJ, Narita M, Muhlemann K. Stenotrophomonas maltophilia: an emerging opportunist human pathogen. Lancet Infect. Dis. 9(5), 312-323 (2009).
55. Munoz JL, Garcia MI, Munoz S, Leal S, Fajardo M, Garcia-Rodriguez JA. Activity of trimethoprim/sulfamethoxazole plus polymyxin B against multiresistant Stenotrophomonas maltophilia. Eur. J. Clin. Microbiol. Infect. Dis. 15(11), 879-882 (1996).
56. San Gabriel P, Zhou J, Tabibi S, Chen Y, Trauzzi M, Saiman L. Antimicrobial susceptibility and synergy studies of Stenotrophomonas maltophilia isolates from patients with cystic fibrosis. Antimicrob. Agents Chemother. 48(1), 168-171 (2004).
57. Zelenitsky SA, Iacovides H, Ariano RE, Harding GK. Antibiotic combinations significantly more active than monotherapy in an in vitro infection model of Stenotrophomonas maltophilia. Diagn. Microbiol. Infect. Dis. 51(1), 39-43 (2005).
58. Falagas ME, Valkimadi PE, Huang YT, Matthaiou DK, Hsueh PR. Therapeutic options for Stenotrophomonas maltophilia infections beyond co-trimoxazole: a systematic review. J. Antimicrob. Chemother. 62(5), 889-894 (2008).
59. Abbott IJ, Slavin MA, Turnidge JD, Thursky KA, Worth LJ. Stenotrophomonas maltophilia: emerging disease patterns and challenges for treatment. Expert Rev. Anti Infect. Ther. 9(4), 471-488 (2011).
60. Chung HS, Hong SG, Kim YR et al. Antimicrobial susceptibility of stenotrophomonas maltophilia isolates from Korea, and the activity of antimicrobial combinations against the isolates. J. Korean Med. Sci. 28(1), 62-66 (2013).
61. Wood GC, Underwood EL, Croce MA, Swanson JM, Fabian TC. Treatment of recurrent Stenotrophomonas maltophilia ventilator-associated pneumonia with doxycycline and aerosolized colistin. Ann. Pharmacother. 44(10), 1665-1668 (2010).